article · International Journal of Hematology-Oncology and Stem Cell Research
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL) and is characterized by a heterogeneous clinical course and variant stage involvement. Indolent disease is usually observed in its early stages. However, the treatment options for patients with advanced MF are limited and have poor outcomes. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment for refractory cases. Here, we describe the case of a 34-year-old man who was diagnosed with MF at an advanced stage. Eight months before allo-HSCT, the patient received six courses of polychemotherapy based on cyclophosphamide, doxorubicin, vincristine, and prednisolone, which were administered every three weeks. A partial response was obtained. He underwent allo-HSCT after a myeloablative conditioning regimen and remained in complete remission (CR) for 26 months posttransplantation. Our findings confirm that allo-HSCT can be a curative option for refractory MF
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.18502/ijhoscr.v19i2.18557
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
